Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amikacin + penicillin
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo Company
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular, Regional Perfusion
01
Overview
A combination antibiotic therapy consisting of amikacin (an aminoglycoside) and penicillin (a beta-lactam). This combination leverages synergistic effects to treat various bacterial infections, particularly severe gram-negative infections. Amikacin works by blocking bacterial protein synthesis by binding to the 30S ribosomal subunit, while penicillin inhibits bacterial cell wall synthesis. The combination has shown efficacy in treating serious infections including septicemia, particularly in immunocompromised patients.
- Other names
- amikacin plus penicillin GAmik-Pen
02
Targets
Beyond the preview
Go deeper on amikacin + penicillin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amikacin + penicillin.